Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives
Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will need to lay off staff.
Researchers were examining …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.